5′-Phosphate and 5′-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 902-914

  Kumar, T Santhosh ^a   Yang, Tiehong ^b   Mishra, Shilpi ^a   Cronin, Chunxia ^b   Chakraborty, Saibal ^a   Shen, Jian Bing ^b   Liang, Bruce T ^b   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 1 [(DIETHYLPHOSPHATE)METHYL] 2,3 (DIHYDROXY)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 1 [(DIISOPROPYLPHOSPHATE)METHYL] 2,3 (DIHYDROXY)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 2,3 (DIHYDROXY) 1 [(DIETHYLPHOSPHATE)DIDEUTEROMETHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 2,3 (DIHYDROXY) 1 [(TERT BUTYLPHOSPHATE)METHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 2,3 (O ISOPROPYLIDENE) 1 [(DI TERT BUTYLPHOSPHATE) DIDEUTEROMETHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN 9 YL) 2,3 (O ISOPROPYLIDENE) 1 [(DIETHYLPHOSPHATE)DIDEUTEROMETHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLORO 9H PURIN YL) 1 [PHOSPHORYLOXYDIDEUTEROMETHYL] 2,3 DIOL BICYCLO[3.1.0] HEXANE; 4 (6 AMINO 2 CHLORO PURIN 9 YL) 2,3 (DIHYDROXY) 1 [MONOPHOSPOROTHIOATE]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 2,3 (DIHYDROXYL) 1 [HYDROXYDEUTEROMETHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [ O,O DIETHYL METHYL PHOSPHOROTHIOATE] 2,3 (O ISOPROPYLIDINE)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [HYDROXYDEUTEROMETHYL] 2,3 (O ISOPROPYLIDINE)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [IODOMETHYL] 2,3 (O ISOPROPYLIDINE)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [O,O DIETHYL METHYL PHOSPHORODITHIOATE] 2,3 (DIHYDROXYL) BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [O,O DIETHYL METHYL PHOSPHORODITHIOATE] 2,3 (O ISOPROPYLIDINE)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [O,O DIETHYL METHYL PHOSPHOROTHIOATE] 2,3 (DIHYDROXYL) BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [O,O DIETHYL O METHYL PHOSPHOROTHIOATE] 2,3 (O ISOPROPYLIDINE) BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 1 [O,O DIETHYL O METHYL PHOSPHOROTHIOATE] 2,3 (O ISOPROPYLIDINE)BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 2,3 (DIHYDROXY) 1 [IODOMETHYL]BICYCLO[3.1.0]HEXANE; 4 (6 AMINO 2 CHLOROPURIN 9 YL) 2,3 O (ISOPROPYLIDENE)BICYCLO[3.1.0]HEXANECARBOXYLATE; 4 (6 AMINO 2 CHLOROPURIN 9 YL] 2,3 (DIHYDROXYL)BICYCLO[3.1.0]HEXANECARBOXYLATE; 4' (6 AMINO 2 CHLOROPURIN 9 YL) 1' [DIISOPROPYL ETHENYLPHOSPHONATE] 2,3 (DIHYDROXY)BICYCLO[3.1.0]HEXANE; 4' (6 AMINO 2 CHLOROPURIN 9 YL) 2',3' (HYDROXY)BICYCLO[3.1.0]HEXANE PHOSPHONATE; 4' (6 AMINO 2 IODOPURIN 9 YL) 2',3' (DIHYDROXY)BICYCLO[3.1.0]HEXANE PHOSPHONATE; 4' (6 AMINO 2 IODOROPURIN 9 YL) 2',3' (DIHYDROXY) 1' (PHOSPHONOMETHYLENE)BICYCLO[3.1.0]HEXANE; 5' PHOSPHATE; 5' PHOSPHONIC ACID ESTER; ADENOSINE PHOSPHATE; METHANOCARBA ADENOSINE; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADENOSINE; CARDIOTONIC AGENT; DRUG DERIVATIVE; ESTER; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS; ANIMAL; CHEMISTRY; DISEASE MODEL; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ESTERS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MYOCARDIAL ISCHEMIA; ORGANOPHOSPHONATES; PHOSPHATES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

MLCS; MLOWN;

EID: 84873898145     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301372c     Document Type: Article

References (23)

1. Coddou, C.; Yan, Z.; Obsil, T.; Huidobro-Toro, J. P.; Stojilkovic, S. S. Activation and regulation of purinergic P2X receptor channels Pharmacol. Rev. 2011, 63, 641-683
2. 4 receptors FASEB J. 2006, 20, 277-284
3. 4 receptors in heart failure: rescuing the calsequestrin- overexpression model of cardiomyopathy Am. J. Physiol. 2004, 287, H1096-H1103
4. Shen, J. B.; Cronin, C.; Sonin, D.; Joshi, B. V.; Carolina, M.; Nieto, G.; Harrison, D.; Jacobson, K. A.; Liang, B. T. P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy. Implications for the treatment of heart failure Am. J. Physiol.: Heart Circ. Physiol. 2007, 292, H1077-H1084
5. Kumar, T. S.; Zhou, S. Y.; Joshi, B. V.; Balasubramanian, R.; Yang, T.; Liang, B. T.; Jacobson, K. A. Structure-activity relationship of (N)-methanocarba phosphonate analogues of 5′-AMP as cardioprotective agents acting through a cardiac P2X receptor J. Med. Chem. 2010, 53, 2562-2576
6. 1 receptor agonists J. Med. Chem. 2002, 45, 2090-2100
7. Joshi, B. V.; Melman, A.; Mackman, R. L.; Jacobson, K. A. Synthesis of ethyl (1 S,2 R,3 S,4 S, 5 S)-2,3- O -(isopropylidene)-4-hydroxy-bicyclo[3.1.0] hexane-carboxylate from l -ribose: a versatile chiral synthon for preparation of adenosine and P2 receptor ligands Nucleosides, Nucleotides Nucleic Acids 2008, 27, 279-291
8. Dunn, P. M.; Kim, H. S.; Jacobson, K. A.; Burnstock, G. Northern ring conformation of methanocarba-adenosine 5′-triphosphate required for activation of P2X receptors Drug Dev. Res. 2004, 61, 227-232
9. Liu, X.; Moody, E. C.; Hecht, S. S.; Sturla, S. J. Deoxygenated phosphorothioate inositol phosphate analogs: synthesis, phosphatase stability, and binding affinity Bioorg. Med. Chem. 2008, 16, 3419-3427
10. Shao, L.; Abolin, C.; Hewitt, M. C.; Koch, P.; Varney, M. Derivatives of tramadol for increased duration of effect Bioorg. Med. Chem. Lett. 2006, 16, 691-694
11. Zhou, S. Y.; Mamdani, M.; Qanud, K.; Shen, J. B.; Pappano, A.; Kumar, T. S.; Jacobson, K. A.; Hintze, T.; Recchia, F. A.; Liang, B. T. Treatment of heart failure by a methanocarba derivative of adenosine monophosphate. Implication for a role of cardiac P2X purinergic receptors J. Pharmacol. Exp. Ther. 2010, 333, 920-928
12. McGuigan, C.; Bellevergue, P.; Jones, B. C. N. M.; Mahmood, N.; Hay, A. J.; Petrik, J.; Karpas, A. Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parent nucleoside analogue Antiviral Chem. Chemother. 1994, 5, 271-277
13. Khan, S. R.; Nowak, B.; Plunkett, W.; Farquhar, D. Bis(pivaloyloxymethyl) thymidine 5′-phosphate is a cell membrane-permeable precursor of thymidine 5′-phosphate in thymidine kinase deficient CCRF CEM cells Biochem. Pharmacol. 2005, 69, 1307-1313
14. Peyrottes, S.; Egron, D.; Lefebvre, I.; Gosselin, G.; Imbach, J. L.; Perigaud, C. SATE pronucleotide approaches: an overview Mini-Rev. Med. Chem. 2004, 4, 395-408
15. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates J. Med. Chem. 2008, 51, 2328-2345
16. Schultz, C. Prodrugs of biologically active phosphate esters Bioorg. Med. Chem. 2003, 11, 885-898
17. Rosowsky, A.; Kim, S.; Ross, J.; Wick, M. M. Lipophilic 5′-(alkyl phosphate) esters of l-beta-arabinofuranosylcytosine and its N -acyl derivatives as potential prodrugs J. Med. Chem. 1982, 25, 171-178
18. Moss, G. P. Extension and revision of the von Baeyer system for naming polycyclic compounds (including bicyclic compounds) Pure Appl. Chem. 1999, 71, 513-529
19. Sonin, D.; Zhou, S. Y.; Cronin, C.; Sonina, T.; Wu, J.; Jacobson, K. A.; Pappano, A.; Liang, B. T. Role of P2X purinergic receptors in the rescue of ischemic heart failure Am. J. Physiol.: Heart Circ. Physiol. 2008, 295, H1191-H1197
20. Shen, J. B.; Shutt, R.; Pappano, A.; Liang, B. T. Characterization and mechanism of P2X receptor-mediated increase in cardiac myocyte contractility Am. J. Physiol.: Heart Circ. Physiol. 2007, 293, H3056-H3062
21. Silvestri, M. A.; Nagarajan, M.; De Clercq, E.; Pannecouque, C.; Cushman, M. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors J. Med. Chem. 2004, 47, 3149-3162
22. Sun, H. Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism Bioorg. Med. Chem. Lett. 2012, 22, 989-995
23. Singh, J. K.; Solanki, A.; Shirsath, V. S. Comparative in-vitro intrinsic clearance of imipramine in multiple species liver microsomes: human, rat, mouse and dog J. Drug Metab. Toxicol. 2012, 3, 4